David F. Penson
Vanderbilt University Medical Center
609 Papers
3.3K Citations
David F. Penson is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 70, co-authored 570 publications. Previous affiliations of David F. Penson include UCLA Medical Center & American Society of Clinical Oncology.
Chat about Author
Papers
Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P): Patient characteristics and treatment persistence.
Kelvin A. Moses,David F. Penson,Neil M. Schultz,Fei Shi,Samuel Wilson,Bruce Brown,Arie Barlev,Scott C. Flanders +7 more
TL;DR: As the use of oral therapies in mCRPC increases, it is crucial to understand treatment persistence as it may be used as an effectiveness outcome.
4
•Journal Article
The influence of provider characteristics and market forces on response to financial incentives.
Brock O'Neil,Mark D. Tyson,Amy J. Graves,Daniel A. Barocas,Sam S. Chang,David F. Penson,Matthew J. Resnick +6 more
TL;DR: Responsiveness to financial incentives in cancer care is associated with high market provider density, profit-maximizing billing behavior, and lack of competing financial ownership interests.
4
The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer
C.J. Stimson,Matthew J. Resnick,Matthew J. Resnick,Sanjay G. Patel,Harras B. Zaid,Michael S. Cookson,David F. Penson,David F. Penson,Joseph A. Smith,Sam S. Chang,Daniel A. Barocas +10 more
TL;DR: Race, insurance status, income and hospital volume demonstrated significant between‐region variation as predictors of treatment with radical cystectomy/pelvic lymph node dissection and the effect of these factors varies by geographic region.
4
•Journal Article
Validation of a staging system for evaluating prognosis in prostate cancer.
TL;DR: In this paper, the authors validated a previously published clinical-anatomic staging system for evaluating prognosis in prostate cancer and explored the predictive ability of additional factors such as prostate specific antigen (PSA) and Gleason score.
4